Battiston L, Tulissi P, Moretti M, Pozzato G
Institute of Clinical Medicine, University of Trieste, Italy.
Pharmacol Toxicol. 1997 Dec;81(6):247-52.
Since some antisecretory drugs such as cimetidine and ranitidine, interfere with ethanol metabolism by inhibition of hepatic and/or gastric alcohol dehydrogenase, we investigated the effect of lansoprazole, a new protonic pump inhibitor, on gastric and hepatic alcohol dehydrogenase activity. We also compared the lansoprazole effect with that of omeprazole and cimetidine, respectively. Ethanol blood concentration after oral intake or intravenous administration of ethanol was estimated either in normal male human volunteers or in male rats before and after one week pretreatment with lansoprazole, omeprazole and cimetidine. Furthermore, the in vitro effect of these drugs was studied on both human and rat gastric and hepatic alcohol dehydrogenases. Finally, we measured the effect of the treatment on the reduced hepatic glutathione to test the effects of the drugs on first-pass metabolism of ethanol. The results reported in this paper indicate that lansoprazole, as well as omeprazole, does not affect ethanol metabolism, and that protonic pump inhibitors seem to be safer than imidazole-derived drugs in subjects unable to reduce ethanol intake during conditions requiring acid secretion inhibition.
由于一些抗分泌药物如西咪替丁和雷尼替丁，通过抑制肝脏和/或胃中的乙醇脱氢酶来干扰乙醇代谢，我们研究了新型质子泵抑制剂兰索拉唑对胃和肝脏乙醇脱氢酶活性的影响。我们还分别将兰索拉唑的作用与奥美拉唑和西咪替丁的作用进行了比较。在正常男性志愿者或雄性大鼠中，在分别用兰索拉唑、奥美拉唑和西咪替丁进行一周预处理前后，测定口服摄入或静脉注射乙醇后的乙醇血药浓度。此外，研究了这些药物对人和大鼠胃及肝脏乙醇脱氢酶的体外作用。最后，我们测量了治疗对肝脏还原型谷胱甘肽的影响，以测试药物对乙醇首过代谢的作用。本文报道的结果表明，兰索拉唑以及奥美拉唑不影响乙醇代谢，并且在需要抑制胃酸分泌的情况下，对于无法减少乙醇摄入量的受试者，质子泵抑制剂似乎比咪唑类药物更安全。
